Headlands Technologies LLC Sells 201 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Headlands Technologies LLC lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,391 shares of the biopharmaceutical company’s stock after selling 201 shares during the period. Headlands Technologies LLC’s holdings in Regeneron Pharmaceuticals were worth $3,840,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. D.A. Davidson & CO. raised its position in Regeneron Pharmaceuticals by 5.1% during the third quarter. D.A. Davidson & CO. now owns 821 shares of the biopharmaceutical company’s stock valued at $863,000 after purchasing an additional 40 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $151,000. Public Sector Pension Investment Board lifted its position in Regeneron Pharmaceuticals by 13.0% in the 3rd quarter. Public Sector Pension Investment Board now owns 4,341 shares of the biopharmaceutical company’s stock worth $4,563,000 after buying an additional 500 shares during the last quarter. Hantz Financial Services Inc. boosted its stake in Regeneron Pharmaceuticals by 87.2% in the third quarter. Hantz Financial Services Inc. now owns 73 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 34 shares in the last quarter. Finally, Captrust Financial Advisors grew its position in Regeneron Pharmaceuticals by 3.4% during the third quarter. Captrust Financial Advisors now owns 9,130 shares of the biopharmaceutical company’s stock valued at $9,597,000 after acquiring an additional 296 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on REGN shares. Wells Fargo & Company reduced their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Citigroup reduced their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Finally, Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $966.88.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $634.23 on Tuesday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $618.51 and a fifty-two week high of $1,211.20. The firm’s 50-day simple moving average is $682.93 and its two-hundred day simple moving average is $791.84. The stock has a market cap of $69.34 billion, a PE ratio of 16.57, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the company earned $11.86 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.